medRxiv preprint doi: https://doi.org/10.1101/19003814; this version posted August 15, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

Title: Measuring Baseline Health with Individual Health-Adjusted Life Expectancy (iHALE)
Authors: Kjell Arne Johansson (MD, PhD)1,2, Jan-Magnus √òkland (MMath)1, Eirin Kr√ºger
Skaftun (MD)1, Gene Bukhman (MD, PhD)3, Ole Frithjof Norheim (MD, PhD)1,4, Matthew
M. Coates (MPH)3, √òystein Ariansen Haaland (PhD)1
Author affiliations:
1. Bergen Centre for Ethics and Priority Setting (BCEPS), Department of Global Public
Health and Primary Care, University of Bergen, Norway
2. Haukeland University Hospital, Department of Addiction Medicine, Bergen, Norway
3. Program in Global NCDs and Social Change, Harvard Medical School, Boston, USA
4. Harvard T. H. Chan School of Public Health, Harvard University, Boston, USA
Corresponding author:
√òystein Ariansen Haaland (PhD)
Mailing address: Department of Global Public Health and Primary Care, University of
Bergen, PO Box 7804, 5020 Bergen, Norway
Email: oystein.haaland@uib.no
Phone: +4755586124
Funding: Bill & Melinda Gates Foundation through the Disease Control Priorities Ethiopia
(DCP-Ethiopia) project grant [OPP1162384] to the University of Bergen and Harvard T.H.
Chan School of Public Health.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/19003814; this version posted August 15, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

1

ABSTRACT

2
3

Objectives: At any point of time, a person‚Äôs baseline health is the number of healthy life

4

years they are expected to experience during the course of their lifetime. In this article we

5

propose an equity-relevant health metric, illness-specific individual Health Adjusted Life

6

Expectancy (iHALE), that facilitates comparison of baseline health for individuals at the

7

onset of different medical conditions, and allows for the assessment of which patient groups

8

are worse off. A method for calculating iHALE is presented, and we use this method to rank

9

four conditions in six countries according to several criteria of ‚Äúworse off‚Äù as a proof of

10

concept.

11
12

Methods: iHALE measures baseline health at an individual level for specific conditions, and

13

consists of two components: past health (before disease onset) and future expected health

14

(after disease onset). Four conditions (acute myeloid leukemia (AML), acute lymphoid

15

leukemia (ALL), schizophrenia, and epilepsy) are analysed in six countries (Ethiopia, Haiti,

16

China, Mexico, United States and Japan). Data for all countries and for all diseases in 2017

17

were obtained from the Global Burden of Disease Study database. In order to assess who are

18

the worse off, we focus on four measures: the proportion of affected individuals who are

19

expected to attain less than 20 healthy life years (T20), the 25th and 75th percentiles of healthy

20

life years for affected individuals (Q1 and Q3, respectively), and the average iHALE across

21

all affected individuals.

22
23

Results: Even in settings where average iHALE is similar for two conditions, other measures

24

may vary. One example is AML (average iHALE=58.7, T20=2.1, Q3-Q1=15.3) and ALL

25

(57.7, T20=4.7, Q3-Q1=21.8) in the US. Many illnesses, such as epilepsy, are associated with

medRxiv preprint doi: https://doi.org/10.1101/19003814; this version posted August 15, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

1

higher baseline health in high-income settings (average iHALE in Japan=64.3) than in low-

2

income settings (average iHALE in Ethiopia=36.8).

3
4

Conclusion: iHALE allows for the estimation of the distribution of baseline health of all

5

individuals in a population. Hence, baseline health can be incorporated as an equity

6

consideration in setting priorities for health interventions.

medRxiv preprint doi: https://doi.org/10.1101/19003814; this version posted August 15, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

1

INTRODUCTION

2

All health systems have budget constraints and limited resources. Methods for health

3

economic evaluations, like cost-effectiveness analysis (CEA), are essential in health policy

4

and are extensively used to rank health services by their expected efficiency [1]. However,

5

few people endorse strict health maximisation [2], and fairness criteria may be included in

6

such rankings [3, 4]. For example, one may give higher priority to interventions that target

7

those with the most severe illnesses [5-7] , especially in relation to decisions about the pricing

8

and reimbursement of new medicines and devices [8, 9]. Policy makers in countries like

9

Norway [10] and the Netherlands [11] have already started using severity measurement

10

methods.

11
12

In this paper, the terms ‚Äúillness‚Äù, ‚Äúdisease‚Äù and ‚Äúcondition‚Äù are used interchangeably, and

13

include all adverse medical conditions, such as injuries, syndromes, birth defects, and

14

infections. The term ‚Äúseverity of illness‚Äù involves both substantial value disagreements and a

15

wide range of interpretations [12, 13]. To sidestep misunderstandings, we use the concept of

16

‚Äúbaseline health at disease onset‚Äù rather than severity of illness. Three perspectives on how to

17

measure baseline health dominate in the literature. One view considers current health [14],

18

one considers health over future years [15], and one considers health over the lifetime [16-

19

18]. In this paper we conform to the latter, and focus on how a particular illness is expected to

20

affect the total lifetime health achieved by an individual before they die [18]. This includes

21

both the past (before disease onset) and future (after disease onset). Clinical definitions of

22

severity of illness often include urgency, but our definition of baseline health does not.

23

Urgency pertains to the timing of treatment and how this influences the prognosis of a

24

condition. Conditions with a low baseline health at onset, like multiple sclerosis in young

25

patients, do not necessarily require urgent interventions.

medRxiv preprint doi: https://doi.org/10.1101/19003814; this version posted August 15, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

1
2

The Global Burden of Disease (GBD) study provides critical summary measures of

3

population health that are relevant when evaluating and comparing health systems [3]. These

4

measures include disability-adjusted life years (DALY) and healthy life expectancy (HALE).

5

DALYs are calculated for a set of diseases by summing the years of life lost (YLL) compared

6

to a reference life expectancy and years lived with disability (YLD) in one particular year due

7

to each disease [19]. For a particular condition and a particular year, YLL is the sum of all the

8

years lost for the individuals who died from the condition during that year. The reference is

9

the age-adjusted life expectancy (LE) from a life table derived from the mortality rates in the

10

locations with the lowest age-specific mortality in the GBD study [20]. YLD, on the other

11

hand, is the sum of the health loss due to the condition during the year across people living

12

with the condition [21]. DALYs aggregated from YLLs and YLDs are a measure of overall

13

population burden. A major limitation of these measures is that they do not capture how the

14

condition affects the distribution of baseline health at onset across individuals in the

15

population.

16
17

We propose a framework where this distribution is an integral part. A key component in this

18

framework is the new metric individual Health Adjusted Life Expectancy (iHALE). In this

19

paper, we present a method for calculating iHALE, and how to use iHALE to rank conditions

20

according to baseline health at onset. We consider four conditions and six countries to

21

illustrate how and why our framework is relevant for priority setting in health care and the

22

measurement of population health.

medRxiv preprint doi: https://doi.org/10.1101/19003814; this version posted August 15, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

1

METHODS

2

Definition of iHALE

3

iHALE measures lifetime health at an individual level for individuals with specific

4

conditions, and consists of two components: past health and future expected health. We

5

obviously do not know the actual time of death for people dying in the future, but we do have

6

some knowledge about the expected distribution across individuals. Consider, for example,

7

two people aged 30 (Ann) and 50 (Bob) who each get a disease. The prognosis for Ann is that

8

she will certainly die within 20 years, but we do not know exactly when. The risk of dying is

9

99% before her 50th birthday, but there is also a 1% chance that she will die in her 51st year.

10

Bob, however, will certainly die before he is 51. For simplicity, we disregard health/disability

11

adjustment for time with illness, and focus only on their age at death. In a lifetime health

12

perspective, there is a 99% probability that Ann will die at a younger age than Bob will.

13

Hence, Ann‚Äôs baseline health is less than Bob‚Äôs in terms of total length of life (past life plus

14

expected future life), even though Bob‚Äôs expected future life is shorter. This is true even if

15

there is a 1% chance that Ann too will die in her 51st year. Health adjustment complicates

16

matters, as we will discuss below, but the principles are the same. Of course, iHALE needs to

17

go beyond hypothetical two-person cases to become a relevant health metric for priority

18

setting in countries with millions of individuals and multiple diseases. iHALE enables

19

comparison of both average baseline health and distribution of baseline health between

20

individuals with different diseases. Methods for calculating the iHALE distribution within

21

disease conditions are presented in the next sections.

22
23

Data

24

For illustrative purposes, we consider four conditions (acute myeloid leukemia (AML), acute

25

lymphoid leukemia (ALL), schizophrenia, and epilepsy) in six countries (Ethiopia, Haiti,

medRxiv preprint doi: https://doi.org/10.1101/19003814; this version posted August 15, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

1

China, Mexico, United States and Japan). The diseases have distinct properties that highlight

2

certain characteristics of iHALE. The two leukemias are fatal, but the incidence of ALL peaks

3

at both young and older age groups, whereas AML incidence peaks at old age groups only.

4

Schizophrenia has large impact on disability over many years, and there are variations in both

5

mortality and morbidity of epilepsy across countries. We consider the leukemias in a US

6

setting, and then we compare schizophrenia and epilepsy across the six countries, representing

7

low-, middle- and high-income settings with different age distributions, levels of health

8

systems development, and access to healthcare among their populations. Data for all countries

9

and for all diseases in 2017 are obtained from the freely available GBD cause of death

10

database [20]. Table 1 describes variables available in the GBD database, and how they are

11

used to derive other important variables.

12
13

[Table 1 here]

14
15

The GBD database gives the parameters from Table 1 in 5-year age groups to age 95. The

16

under-5 age group is split into ‚Äúless than one year old‚Äù (<1 group) and ‚Äú1-4 years old‚Äù. To

17

obtain single-year age estimates, we undertake the following procedures. For pop, we divide

18

the population in the 4- and 5-year age groups evenly by single-year ages, and the terminal

19

age group (95 plus) is divided equally in five parts from 95 to 99. For example, if 500 000

20

individuals are in the 20-24 age group, we will assume that there are 100,000 20-year olds,

21

100,000 21-year olds, and so on. For PD, ID, dw, dwD, q(age), and MD(age), we assume that

22

the rates (or disability weights) are the same for each single-year age in the aggregate age

23

groups. For example, if dwD was 0.2 in the 20-24 age group, we assume that it was 0.2 for 20-

24

year olds, 0.2 for 21-year olds, and so on.

25

medRxiv preprint doi: https://doi.org/10.1101/19003814; this version posted August 15, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

1

Part I: Estimating disease-specific individual life expectancy

2

The individual life expectancy (iLE) of an individual is simply

3
4

iLEage

age

LY



age

,

(1)

5
6

where ‚Äúage‚Äù is the age of the individual and LYfuture is the number of life years each

7

individual has left to live at their respective age. LYfuture is not known until the individual

8

actually dies, but its distribution can be estimated as follows. First, we define Y, the

9

maximum age in our lifetable, by setting the chance of surviving from age Y to Y+1 to zero.

10

Then we calculate the number of people who are expected to die at different ages in the Y

11

years to come. This can be done using an upper diagonal Y

1

Y

1

matrix,

12
13
N ,

N ,

N ,



N ,



N ,

N ,



N ,





N ,



 







 









14









N ,



.

(2)



N , 

15
16

In each element of ‚Ñï

17

For example, N3,12 is the number of today‚Äôs 3-year-olds who will die at age 12. Each N

18

calculated using standard lifetable methodology [22], based on the assumption that q(age)

19

remains the same in the future. In other words, N,

20

death for an individual with current age c. We see that summing the rows, ‚àë

21

the population age structure (pop). Further, summing the columns, ‚àë

22

number of people that we expect to die at age d. That is, the number of people for which

23

iLE

iLE,

N , the c denotes the current age and the d denotes the age at death.
c,d

, N, , ‚Ä¶ , N, 

c,d

is

is the distribution of age at

N,

N,

, yields

, gives the

. The sum ‚àë ‚àë N, is the total current number of people at all ages. In our

medRxiv preprint doi: https://doi.org/10.1101/19003814; this version posted August 15, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

1

calculations, we use Y=99. Note that it follows from the assumption of a static q(age) that

2

average LYfuture is the same as LE. From (1) we see that iLE is dominated by LYfuture for

3

young children, and by age for very old people.

4
5

Before we break the analysis into diseases, we start by analyzing total figures for one country,

6

as this is familiar for most readers and perhaps more intuitive. Figure 1 shows the distribution

7

of iLE for all age groups in the total population of the United States in 2017. In the left panel,

8

individuals alive in 2017 are ranked by their current age, and the right panel ranks them by

9

iLE. Now we can see that around 22 million people (7%) in the US have iLE < 60 years. As

10

expected, the proportion is much higher in Ethiopia (16%) and Haiti (20%). Note that by

11

simply focusing on LE, we would know nothing about such distributional characteristics.

12
13

[Figure 1 here]

14
15

For individuals who get a disease, D, at a particular age, (1) becomes

16
17

iLE age

age



LY 

age

.

(4)

18

is calculated similarly to LYfuture. Instead of pop(age), we use I age

19

LY 

20

(Table 1), and instead of mortality rates for the general population, we use those of

21

individuals with condition D, qD (Table 1). For diseases with very high mortality, LY 

22

will be small for all ages, and iLED will therefore to a large extent depend on age alone. If the

23

excess mortality is low, the situation resembles that of (1).

24



pop age

medRxiv preprint doi: https://doi.org/10.1101/19003814; this version posted August 15, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

1

Figure 2 shows the estimated iLE distribution among the 10,600 people with incident cases of

2

acute myeloid leukemia (AML) and 1,950 people with incident cases of acute lymphoid

3

leukemia (ALL) in the United States in 2017. The LE was 67.9 for AML and 67.6 for ALL.

4

However, as the figure shows, the mean age of onset in the United States in 2017 was 62.5 for

5



AML and 45.6 for ALL, and mean LY 
was 5.4 years, whereas LY 
was 22 years.

6

Once again, we see that important information about baseline health is lost when focusing on

7

LE only.

8
9

[Figure 2 here]

10
11

Part II. Adjust for morbidity

12

Non-fatal morbidities should also be taken into account when assessing baseline health at

13

disease onset, so that one can compare across fatal and non-fatal diseases with different

14

impacts on health loss. This includes estimating health adjusted age (HAA) and future health

15

adjusted life years (HALYfuture). Expanding on (4), we get

16
17

iHALE  age

HAA



age



HALY

age

,

(5)

18
19

In this section we will explain how to estimate HAApast and HALY using the background

20

disability, dw, and the excess disease-specific disability, dwD (Table 1).

21
22

Figure 3 outlines the conceptual structure of the iHALE method, where both past and future

23

health is summed for each individual with one of the four diseases AML, ALL, epilepsy and

24

schizophrenia.

25

medRxiv preprint doi: https://doi.org/10.1101/19003814; this version posted August 15, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

1

[Figure 3 here]

2
3

HAApast is calculated as follows,

4
5



HAA

c 



‚àë '1  dwi*

,

(6)

6
7

where, c is current age and dw(i) is the background disability from age ‚Äúi‚Äù to ‚Äúi+1‚Äù (Table 1).

8

We assume that conditions are independent and that past dw are the same regardless of

9

current disease status.

10
11

To account for future non-fatal health loss caused by a disease, D, we use disease specific

12

excess disability, dwD, and mortality, qD, as calculated in Table 1. However, mortality risk is

13

returned from qD to q after a period of increased mortality (PIM), and morbidity returns from

14

dwD to dw after a period of increased disability (PID) (Table 1 expands on PIM and PID).

15
16

In Figure 3 we see from the AML examples how two different persons may fare under the

17

same PIM and PID. Person 1 survives long enough that both mortality and morbidity return to

18

those of the background population, and then dies at age 63 from a different cause, whereas

19

Person 2 dies during the PIM.

20
21

Future health adjusted life years, as a function of current age and age at death, is

22
0.5

23


c, d
HALY

+

c

0.5  '0.5



dw

d 



/1  dw


d 0 , c



‚àë dw

i*, c 1
, c 2

24

d
3

, (7)

medRxiv preprint doi: https://doi.org/10.1101/19003814; this version posted August 15, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

1

where c is current age and d is age at death. As in (6), dw i is the disability weight from

2

age ‚Äúi‚Äù to ‚Äúi+1‚Äù. However, because we estimate future health loss, the disability weight must

3

be adjusted during PID. This means that the disability increased for a period of PID years

4

after onset before returning to that of the general population (Table 1).

5
6

We next set out to estimate the iHALE distribution in a population. This is done in several

7

steps. First, we create one matrix for past health, and one for future health. The matrix for past

8

health is

9
0


10



4



0





HAA


1 






2 

























HAA



0


HAA



HAA



1 
2 




,



(8)





HAA

Y

11
12

where HAApast is from (6). Because the row number represents current age, we see that the

13

elements are the same within each row. In other words, your past health only depends on your

14

current age, and not your future age at death (column number).

15
16

In the matrix for future health, we need to account for both current age and age at death.

17

Using HALY from (7), we get

18




19


4

HALY

0,0

0,1

HALY




HALY
1, Y 




















Adding past and future health yields






HALY
1,1

20
21



HALY




HALY

0, Y





Y, Y

.

(9)

medRxiv preprint doi: https://doi.org/10.1101/19003814; this version posted August 15, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

1
2



4

4





4

.

(10)

3
4

In 4
, row number c gives iHALE for individuals who are c years old, whereas column


5

number d gives the iHALE for individuals who will die at age d. As opposed to the discrete

6

iLE, iHALE is continuous. For example, one individual who dies at age 80 may have an

7

iHALE equal to 67.3 healthy years, whereas another could have achieved 67.4 or 67.5.

8

Because we do not have access to data on individuals, every individual with the same

9

condition and the same age of onset is assumed to have the same iHALE distribution. In ‚ÑïiLE

10

from (2), we obtained these distributions by considering the rows. This information is not

11

available in 4
, but we may create a new matrix, 

 , where the elements correspond to

12

those of  , but are calculated using q
instead of q (Table 1).


13


Pairing all elements in 
yields the iHALE
 with the corresponding element in 4

14

distribution for all values of c and d for the disease D.

15
16

In 
 we use incidence to identify those who get the disease D each year, which is

17

especially useful for life-long conditions. See Figure A1 (Appendix) for details on incidence

18

assumptions that are being used in iHALE calculations for AML and ALL in the US.

19
20

[Figure 4 here]

21
22

Figure 4 shows that even though average iHALE is similar for AML (58.7) and ALL (57.7),

23

the distribution across individuals is different. For example, in the US we expect 4.7% of

24

individuals with ALL to have iHALE < 20 (T20), compared with only 2.1% for individuals

25

with AML. Hence, considering risk of a low baseline health, individuals with ALL would be

medRxiv preprint doi: https://doi.org/10.1101/19003814; this version posted August 15, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

1

worse off. Still, the 75th percentile (Q3) of iHALE for individuals with ALL (71.3) was higher

2

than in people with AML (67.9), so with respect to chance of a high baseline health

3

individuals with AML would be the worse off. Again, this highlights the need for

4

distributional concerns in policy making.

5
6

Data availability statement

7

The data used to create the tables and figures in this paper can be accessed without restrictions

8

at https://doi.org/10.5281/zenodo.3258330.

medRxiv preprint doi: https://doi.org/10.1101/19003814; this version posted August 15, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

1

RESULTS

2

Table 2 shows average iHALE, T20, Q1 and Q3 for ALL, AML, schizophrenia and epilepsy

3

in six countries (see Appendix Table A4 for 200 NCDI conditions). Rank orders of the four

4

conditions varied both between countries and according to measure of who is worse off.

5
6

[Table 2 here]

7
8

The iHALE distribution for schizophrenia was similar across the six settings, although Japan

9

stands out in a positive manner. The difference in average iHALE for schizophrenia between

10

the US and Japan was larger than the difference between the US and Ethiopia (Haiti 40.7,

11

Ethiopia 41.1, China 45.7, Mexico 44.4, US 43.5, Japan 48.6). The same applied to the

12

quartiles. T20, the proportion of people with iHALE <20, was low across countries for

13

schizophrenia, which is reasonable, as schizophrenia rarely manifests in childhood.

14

Variability in average iHALE for epilepsy between countries was high (Ethiopia 36.8, Haiti

15

39.5, Mexico 53.5, China 56.6, US 58.8, Japan 64.3). In addition, there is much more unequal

16

iHALE distribution for epilepsy in countries with low average iHALE (difference between

17

quartiles (Q3-Q1) was 19.9 in Ethiopia, 17.9 in Haiti, 15.2 in China, 14.9 in Mexico, 13.3 in

18

Japan, and 13.2 in the US). Further, only 0.6% of the Japanese had iHALE under 20, but the

19

number was 14.0% among Ethiopians and 8.4% among Haitians.

medRxiv preprint doi: https://doi.org/10.1101/19003814; this version posted August 15, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

1

DISCUSSION

2

According to fairness concerns, limited health care resources should be allocated to

3

interventions that benefit the worse off in society [5-7, 18]. In this paper, we present a

4

quantitative method for identifying the worse off by estimating the distribution of lifetime

5

health across individuals in the same disease category. We show how two conditions, ALL

6

and AML, with similar LEs and average iHALEs have substantially different distributions of

7

iHALE. In addition, we show how iHALE varies across countries, and demonstrate how the

8

iHALE distribution captures different aspects of the fact that diseases are typically more

9

severe in low-income than in high-income countries. Our new framework important for

10

priority setting because it can be used to assign extra value to health gains from interventions

11

targeting the worse off. The relevance of iHALE is particularly good for preventive

12

interventions for a disease where you are likely to capture benefits across a range of ages (for

13

example treating strep throat in school children to prevent rheumatic heart disease).

14
15

Sullivan, in 1971, suggested how morbidity adjustment could be done for LE to get HALE by

16

modifying the standard life table model to estimate the expected duration of a condition by

17

exposing a birth cohort of a disease specific mortality and disability rate over a lifetime [22].

18

Sullivan‚Äôs method estimates average expected years of healthy life rather than the distribution

19

of iHALE between individuals as done in this paper.

20
21

In this article we present iHALE as an achievement measure, but it may be more intuitive to

22

present baseline health at disease onset as a shortfall from what individuals could potentially

23

achieve. iHALE could be converted to an individual gap-measure (e.g. iDALY) by using the

24

YLL method applied in GBD. Shortfall in life years could be calculated for each individual at

25

disease onset by using the lowest mortality by age in the world as a reference. Shortfall in

medRxiv preprint doi: https://doi.org/10.1101/19003814; this version posted August 15, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

1

disabilities could use the lowest YLD rates across countries as a reference for disability

2

shortfall. However, disease shortfall measures are beyond the scope of this paper.

3
4

PIM and PID, as presented in this paper, have some limitations. They could be different for

5

the same condition across settings, as would be the case for conditions, like HIV, that can be

6

treated or controlled more effectively in some countries than in others. Part of these

7

differences should be captured in the excess mortality differences between countries in our

8

current analysis, but the durations of the periods are also likely to vary. Additionally, PIM and

9

PID do not capture the nature of conditions where mortality and morbidity have complicated

10

temporal patterns. For example, the peak increase in mortality risk for HIV patients is about a

11

decade after onset. At a conceptual level, these obstacles are easy to handle. One simply must

12

estimate PIM and PID for all conditions under consideration in all relevant settings. However,

13

the empirical task of getting precise PIM and PID estimates is not trivial.

14
15

Understanding the underlying reasons for differences in the distribution of iHALE can have

16

policy implications. Observed differences in the distribution of iHALE between countries can

17

originate from a number of reasons. It is important to note that as a measure of lifetime health

18

among people with a specific condition, iHALE is influenced by mortality risk and morbidity

19

from other causes, as well as by the age at which the disease occurs. Thus, variation in iHALE

20

could be caused from differences in demography and epidemiology at the country level, or

21

from variations in access to health care that underlie differences in disease-specific morbidity

22

or mortality rates. The relative contribution of each of these differences to the overall

23

difference in iHALE between countries depends on which countries are being compared. How

24

to quantify the role of each factor is discussed further in Appendix (Figure A2).

25

medRxiv preprint doi: https://doi.org/10.1101/19003814; this version posted August 15, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

1

To measure the true disease-specific baseline health distribution, the past health would be

2

calculated using observed past disability for individuals. The data available for our

3

calculations were limited in several ways. There was no individual-level morbidity and

4

mortality information, so we used population averages. This meant that we were unable to

5

account for correlation between illnesses. For example, people who die of a car accident at

6

age 45 may be different on average from those who die of a myocardial infarction at age 45

7

regarding lifestyle (smoking, exercise, diet) and biology (metabolism, genetics), which could

8

affect the risk of other morbidities. As a result, our estimates of iHALE may be high

9

(overestimate baseline health) for illnesses that are often experienced with comorbidities

10

because they do not capture the higher burden from the associated illnesses. Conversely, our

11

estimates of iHALE may be low (underestimate baseline health) for illnesses that have few

12

comorbidities. These limitations are especially evident in mental health conditions. The GBD

13

estimates do not attribute any mortality to mental health disorders; however, we know that

14

patients with mental health disorders have higher mortality risk compared to the general

15

population [23-25]. Our schizophrenia iHALE results are additionally limited by distributions

16

of disability weights that do not vary along with treatment availability across countries [26].

17

The limited time series available from the GBD meant that we did not have complete

18

historical average disability rates. For consistency, we used age-specific rates of disability for

19

the calculations of past health; however, health achievement in a real population would use

20

historical disability information if available.

medRxiv preprint doi: https://doi.org/10.1101/19003814; this version posted August 15, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

1

CONCLUSION

2

Increasing availability of demographic and epidemiologic data creates opportunities for

3

quantifying the baseline health at disease onset to guide priority setting in health care. Policy

4

makers, supported by the ethical literature, are concerned about giving higher priority to the

5

worse off. However, the impact of such fairness concerns to health policy does not match the

6

impact cost-effectiveness analysis has had on policy the last decades. Data availability and

7

lack of rigorous methods for quantifying the baseline health at disease onset are likely

8

contributing factors to the negligence of the worse off in de facto health care priority setting.

9

Here we have presented a method for calculating iHALE and illustrate with examples how

10

and why a metric that is sensitive to distribution is relevant for priority setting in health care

11

and the measurement of population health. We lay the foundations for undertaking detailed

12

calculations of disease-specific iHALE in multiple countries.

medRxiv preprint doi: https://doi.org/10.1101/19003814; this version posted August 15, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

1

LIST OF ABBREVIATIONS:

2

individual Health Adjusted Life Expectancy (iHALE), individual life expectancy (iLE);

3

Period of Increased Mortality (PIM); Period of Increased Disability (PID); health adjusted age

4

(HAA); cost-effectiveness analysis (CEA); Global Burden of Diseases (GBD); disability-

5

adjusted life-years (DALY); healthy life years (HALY); years of life lost (YLL); years lived

6

with disability (YLD); acute myeloid leukemia (AML); acute lymphoid leukemia (ALL)

medRxiv preprint doi: https://doi.org/10.1101/19003814; this version posted August 15, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

REFERENCES
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.

Greenberg, D. and P.J. Neumann, Cost-Effectiveness Analysis Expands its Reach Worldwide.
Value Health Reg Issues, 2016. 10: p. 101-102.
Cookson, R., et al., Using Cost-Effectiveness Analysis to Address Health Equity Concerns.
Value Health, 2017. 20(2): p. 206-212.
Ottersen, T., et al., Making fair choices on the path to universal health coverage. Bull World
Health Organ, 2014. 92(6): p. 389.
World Health Organization, Making fair choices on the path to universal health coverage.
2014, World Health Organization: Geneva.
Norheim, O.F., et al., Guidance on priority setting in health care (GPS-Health): the inclusion of
equity criteria not captured by cost-effectiveness analysis. Cost Eff Resour Alloc, 2014. 12: p.
18.
Johri, M. and O.F. Norheim, Can cost-effectiveness analysis integrate concerns for equity?
Systematic review. Int J Technol Assess Health Care, 2012. 28(2): p. 125-32.
Nord, E. and R. Johansen, Concerns for severity in priority setting in health care: a review of
trade-off data in preference studies and implications for societal willingness to pay for a
QALY. Health Policy, 2014. 116(2-3): p. 281-8.
Mirelman, A., et al., Decision-making criteria among national policymakers in five countries: a
discrete choice experiment eliciting relative preferences for equity and efficiency. Value
Health, 2012. 15(3): p. 534-9.
Tanios, N., et al., Which criteria are considered in healthcare decisions? Insights from an
international survey of policy and clinical decision makers. Int J Technol Assess Health Care,
2013. 29(4): p. 456-65.
Ottersen, T., et al., A new proposal for priority setting in Norway: Open and fair. Health
Policy, 2016. 120(3): p. 246-51.
van de Wetering, E.J., et al., Balancing equity and efficiency in the Dutch basic benefits
package using the principle of proportional shortfall. Eur J Health Econ, 2013. 14(1): p. 10715.
Barra, M., et al., Severity as a Priority Setting Criterion: Setting a Challenging Research
Agenda. Health Care Anal, 2019.
Olsen JA., Beyond cost-effectiveness: priority setting, in Principles in Health Economics and
Policy, Olsen JA., Editor. 2017, Oxford Scholarship Online.
Nord, E., Cost-value analysis in health care: making sense out of QALYs. Cambridge studies in
philosophy and public policy. 1999, Cambridge: Cambridge University Press. XXIII, 157 s.
Scanlon, T.M., Kamm on the disvalue of death. J Med Ethics, 2015. 41(6): p. 490.
Adler, M., Well-Being and Fair Distribution: Beyond Cost-Benefit Analysis. 2011: Oxford
University Press.
Otsuka, M. and A. Voorhoeve, Why It Matters That Some Are Worse Off Than Others: An
Argument against the Priority View. PHILOSOPHY & PUBLIC AFFAIRS, 2009. 37(2): p. 171-199.
Ottersen, T., Lifetime QALY prioritarianism in priority setting. J Med Ethics, 2013. 39(3): p.
175-80.
Institute for Health Metrics and Evaluation and collaborators, Global Burden of Disease study
(2017, 2016, 2015, 2013 and 2010). Lancet, 2018, 2017, 2016, 2014, 2012.
GBD Causes of Death Collaborators, Global, regional, and national age-sex-specific mortality
for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for
the Global Burden of Disease Study 2017. Lancet, 2018. 392(10159): p. 1736-1788.
Schroeder, S.A., Incidence, prevalence, and hybrid approaches to calculating disabilityadjusted life years. Popul Health Metr, 2012. 10(1): p. 19.
Sullivan, D.F., A single index of mortality and morbidity. HSMHA Health Rep, 1971. 86(4): p.
347-54.

medRxiv preprint doi: https://doi.org/10.1101/19003814; this version posted August 15, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

1
2
3
4
5
6
7
8

23.
24.
25.
26.

Thornicroft, G., Physical health disparities and mental illness: the scandal of premature
mortality. Br J Psychiatry, 2011. 199(6): p. 441-2.
Lawrence, D., S. Kisely, and J. Pais, The epidemiology of excess mortality in people with
mental illness. Can J Psychiatry, 2010. 55(12): p. 752-60.
Vigo, D., G. Thornicroft, and R. Atun, Estimating the true global burden of mental illness.
Lancet Psychiatry, 2016. 3(2): p. 171-8.
Burstein, R., et al., Estimating distributions of health state severity for the global burden of
disease study. Popul Health Metr, 2015. 13: p. 31.

medRxiv preprint doi: https://doi.org/10.1101/19003814; this version posted August 15, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

1
2
3

Table 1: Description of data and variables used to calculate individual Health Adjusted Life

4

Expectancy (iHALE), the GBD 2017 study [3] is source for all calculations.

TABLES

Variable

Description

PIM

Period of increased mortality.
From expert opinions.
Number of years with increased mortality after disease onset. The rate at which
mortality declines in the PIM is specific for each condition.
For simplicity, PIM=100 for chronic diseases. We use PIM=5 for the leukemias.

PID

Period of increased disability.
From expert opinions.
Number of years with increased disability after disease onset. The rate at which
disability declines in the PID is specific for each condition.
For simplicity, PID=100 for chronic diseases. We use PID=5 for the leukemias.

pop

Population size, per 5-year age interval.
From GBD 2017.
Transformed to 1-year age intervals by distributing individuals evenly across the five
years.

PD

Prevalence (per population) of disease per 5-year age interval.
From GBD 2017.
Assumed to be the same in all 1-year intervals.

ID

Incidence (per population) of disease per 5-year age interval.
From GBD 2017.
Assumed to be the same in all 1-year intervals.

MD

Disease specific probability of death per 5-year age interval, for total population.

medRxiv preprint doi: https://doi.org/10.1101/19003814; this version posted August 15, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

From GBD 2017.
Assumed to be the same in all 1-year intervals.
q

All cause probability of death per 5-year age interval, for total population (background
mortality). From GBD 2017.

q  M  
Assumed to be the same in all 1-year intervals.
YLDD

Years Lived with Disability of disease per 5-year age interval.
From GBD 2017.
Assumed to be the same in all 1-year intervals.

Derived
emD

Excess mortality due to disease (case fatality rate). These are not given directly in
GBD, but can be calculated using


em age    

.

This is the extra risk of dying for individuals with disease that is caused directly by the
disease itself. Note that this is different from MD, which is the risk of dying from a
particular disease for any individual in the population.
qD

Probability of death due to disease and background mortality. These are not given
directly in GBD, but can be calculated using

q age  qage

M age

em age

q age  qage


M age   

.

Substituting emD into qD yields

1 .

medRxiv preprint doi: https://doi.org/10.1101/19003814; this version posted August 15, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

We can see that if PD=1, meaning that all individuals in the population have a disease,
qD simply becomes q. This is also the case if there is no mortality from disease, so that
MD=0.

q

During the period of increased probability of death due to disease, q is used for PIM
years. After the period, q returns to  .

dw

Background disability weight from the population overall (0 is no disability and 1 is
death).

dw 

dwD

   
 .

Average disability weight due to the disease of interest (0 is no disability and 1 is
death).





dw age     .

dw 

During the period of increased disability, the disability weight is

dw   1

1

   



 1

dw

.

After the period, dw returns to that of the background population (dw).
1
2

medRxiv preprint doi: https://doi.org/10.1101/19003814; this version posted August 15, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

1

Table 2: Average individual Health Adjusted Life Expectancy (iHALE), T20, Q1 and Q3 for four

2

conditions in six countries, results from 200 NCDI conditions can be found in the Appendix Table A4

3

(the GBD 2017 study [3] is source for all calculations).

Average iHALE

Acute myeloid
Epilepsy Schizophrenia
leukemia
30.8
36.8
41.1

47.5

41.2

14.1

0.5

Q1

7.8

7.0

26.3

35.6

Q3

61.0

51.7

46.2

46.0

Average iHALE

33.4

33.5

39.5

40.7

T20 (%)

44.4

32.0

8.3

0.5

Q1

9.5

13.5

30.5

35.3

Q3

58.3

51.0

48.4

45.5

Average iHALE

57.5

46.5

56.6

45.7

5.1

15.2

1.8

0.1

Q1

47.4

31.6

50.4

39.3

Q3

71.6

62.8

65.6

51.4

Average iHALE

44.5

39.4

53.5

44.4

T20 (%)

23.7

23.0

2.0

0.2

Q1

20.4

21.4

46.8

38.7

Q3

66.8

56.6

61.7

49.7

Average iHALE

57.7

58.7

58.8

43.5

4.7

2.1

0.7

0.2

Q1

49.5

52.6

53.3

38.2

Q3

71.3

67.9

66.5

47.9

Average iHALE

66.0

62.8

64.3

48.6

1.5

1.6

0.6

0.0

60.7

57.3

59.1

42.1

72.4

54.4

4

Q3
76.6
71.6
T20: Proportion of individuals with disease who attain iHALE > 20.

5

Q1: Attained iHALE for the individual at the 25th percentile

6

Q3: Attained iHALE for the individual at the 75th percentile

Ethiopia

Haiti

China

Mexico

US

Japan

7

T20 (%)

Acute lymphoid
leukemia
33.0

T20 (%)

T20 (%)

T20 (%)
Q1

medRxiv preprint doi: https://doi.org/10.1101/19003814; this version posted August 15, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

1

FIGURES

2

Figure 1: Distribution of individual life expectancy (iLE) for the total US population (2017).

3

Left panel: Distribution by age. On the x-axis, -100 corresponds to the year 1917, and +100

4

corresponds to the year 2117. Years lived before 2017 are observed, whereas years lived after

5

2017 are expected.

6

Right panel: Distribution by iLE.

7
8

Figure 2: Individual life expectancy (iLE) for individuals who got leukemia in the US in

9

2017, sorted according to age at onset. Left panel: Distribution for acute myeloid leukemia

10

(AML). Right panel: Distribution for acute lymphoid leukemia (ALL).

11
12

Figure 3: Outline of the conceptual structure of the individual Health Adjusted Life

13

Expectancy (iHALE) method, where we calculate the sum of past health and expected future

14

health for five individuals with different diseases (AML, ALL, epilepsy and schizophrenia).

15

For a disease D, the dashed black line is background mortality, and the blue line is

16

background mortality added to the excess risk of death caused by D. The orange area is

17

background health loss due to disability (dw), and the red area is health loss caused by D

18

(dwD). The grey area is iHALED. The sum of the grey, orange and red areas constitute iLE.

19

The top solid black line gives a period after the onset of D when the person had a period of

20

increased mortality (PIM). The bottom line gives a similar period of increased disability

21

(PID).

22
23

Figure 4: Distribution of individual Healthy Adjusted Life Expectancy (iHALE) for AML

24

and ALL in the United States in 2017.

25

medRxiv preprint doi: https://doi.org/10.1101/19003814; this version posted August 15, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

1
2
3
4
5
6
7
8
9
10

Appendix
A1 Incidence
Figure A1 shows details on incidence assumption that is being used in iHALE calculations.
[Figure A1 here]
Figure A1: Incidence rates (top) and incidence (bottom) across age groups for AML and
ALL in the United States (2017) [1].

medRxiv preprint doi: https://doi.org/10.1101/19003814; this version posted August 15, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

A2 Decomposition
To illustrate how differences in demography, epidemiology, and disease specific mortality
and morbidity led to differences in average iHALE between Japan and Ethiopia as exemplars,
we took an approach that parallels methods described by Das Gupta [2], creating estimates
using the 64 possible scenarios of the two values for the 6 input factors. For each factor, there
are then 32 pairs of scenarios in which all five other factors remain constant but the factor in
question takes on either Japan or Ethiopia‚Äôs value. To calculate the effect of each factor on the
overall iHALE difference between Ethiopia and Japan, we took the average of the difference
in iHALE between these 32 sets of paired scenarios. Essentially, this is the average effect of
varying that one factor with every possible combination of other factors. Figure A2 shows the
results of this decomposition. As expected, the younger age structure in Ethiopia and the
higher overall mortality contributes substantially to differences in iHALE. However, we also
see that disease-specific mortality differences play a large role for epilepsy, leading to a much
lower iHALE in Ethiopia. The disease-specific disability plays a very small role for
schizophrenia, as discussed in the main text, because of a lack of variation in the distribution
of severity across countries in the input data from the GBD data (see A3). Surprisingly, the
age distribution of incidence contributes to higher iHALE in Ethiopia, a function of the age
distribution of incidence rates from GBD, which tend to be higher at older ages and lower at
younger ages in Ethiopia.
[Figure A2 here]
Fig A2: Difference in iHALE between Japan and Ethiopia for 4 diseases (Acute lymphoid
leukemia, Acute myeloid leukemia, Epilepsy and schizophrenia), decomposed into factors
driving differences.

medRxiv preprint doi: https://doi.org/10.1101/19003814; this version posted August 15, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

1
2
3
4
5
6
7
8
9
10
11
12
13
14

A3 Age-standardized average disability weight
Mental disorders like major depressive disorder (MDD), bipolar disorder, and schizophrenia
show almost no difference in age-standardized average disability weight between high income
and low income countries in GBD, despite higher treatment rates in high income settings. We
might expect the distribution of severity to be more severe in low income settings where
treatment is less available. Differences in iHALE between high and low income settings,
particularly for nonfatal conditions like mental health disorders, are limited by these estimated
severities in GBD. Note the much larger difference in average disability weight for epilepsy.
[Figure A3 here]
Figure A3: Age-standardized average disability weight (YLDs/Prevalence) in High Income
versus Low Income countries by World Bank income groups.
MDD=Major depressive disorder

Table A1 shows results for iHALE for 200 NCDI conditions for Ethiopia, Haiti, China, Mexico, US and Japan.

Table A1: iHALE for 200 NCDI conditions for Ethiopia, Haiti, China, Mexico, US and Japan (T20 is the % with iHALE<20, Q1 is quartile 1
and Q3 is quartile 3).

T20 (%)

Q1

Q3

Average
iHALE

T20 (%)

Q1

Q3

Average
iHALE

T20 (%)

Q1

Q3

Average
iHALE

T20 (%)

Q1

Q3

Average
iHALE

T20 (%)

Q1

Q3

Japan

Average
iHALE

US

Q3

Mexico

Q1

China

T20 (%)

Acne vulgaris
Acute
glomerulonephritis
Acute lymphoid
leukemia
Acute myeloid
leukemia
Adverse effects of
medical treatment
Age-related and other
hearing loss
Age-related macular
degeneration
Alcohol use disorders
Alcoholic
cardiomyopathy
Alopecia areata
Alzheimer's disease
and other dementias
Amphetamine use
disorders
Anorexia nervosa
Anxiety disorders
Appendicitis
Asbestosis
Asthma
Atopic dermatitis
Atrial fibrillation
and flutter
Attentiondeficit/hyperactivity
disorder
Autism spectrum
disorders
Benign and in situ
cervical and uterine
neoplasms

Haiti

Average
iHALE

Ethiopia

63.4
61.0

0.6
5.0

57.5
55.9

71.7
71.0

60.1
56.4

0.7
7.0

53.4
49.4

69.0
68.3

69.0
58.4

0.1
3.1

63.6
47.7

75.5
71.3

67.4
67.1

0.4
1.5

61.5
61.6

75.7
75.8

67.2
69.2

0.2
0.1

62.1
65.1

74.6
75.2

73.2
74.4

0.1
0.1

69.4
71.0

79.3
79.4

33.0

47.5

7.8

61.0

33.4

44.4

9.5

58.3

57.5

5.1

47.4

71.6

44.5

23.7

20.4

66.8

57.7

4.7

49.5

71.3

66.0

1.5

60.7

76.6

30.8

41.2

7.0

51.7

33.5

32.0

13.5

51.0

46.5

15.2

31.6

62.8

39.4

23.0

21.4

56.6

58.7

2.1

52.6

67.9

62.8

1.6

57.3

71.6

58.8

7.2

54.2

71.0

54.4

8.5

47.6

67.5

70.6

0.2

65.9

75.5

66.9

2.2

62.3

75.7

70.5

0.0

66.4

75.2

74.3

0.2

70.9

79.3

66.0

0.1

61.3

72.8

64.1

0.1

59.0

70.9

71.3

0.0

67.4

76.6

71.0

0.0

66.8

77.1

71.0

0.0

67.6

75.9

76.3

0.0

73.2

80.7

69.2

0.0

65.4

73.4

68.0

0.0

64.2

72.4

72.9

0.0

69.5

77.0

73.3

0.0

70.0

77.5

72.8

0.0

69.8

76.7

76.9

0.0

74.3

80.6

59.9
54.4

0.1
4.0

54.3
42.2

67.0
67.4

56.9
42.3

0.1
16.6

50.5
26.6

64.5
57.4

66.0
60.2

0.0
1.5

61.5
55.1

72.1
69.0

62.4
59.6

0.1
2.7

56.0
51.3

70.4
71.2

62.5
62.2

0.0
1.4

56.8
56.3

70.0
71.7

68.4
71.2

0.0
0.7

63.5
67.9

75.0
77.4

63.1
70.2

0.3
0.0

57.7
66.9

70.7
74.3

60.5
68.6

0.3
0.0

54.4
65.1

68.3
73.0

68.8
72.7

0.0
0.0

64.3
69.5

74.7
76.8

67.6
73.5

0.1
0.0

62.4
70.4

74.9
77.6

67.7
72.4

0.0
0.0

63.5
69.3

74.0
76.3

73.2
76.6

0.0
0.0

69.8
74.0

78.7
80.1

55.9

0.2

50.4

63.4

54.3

0.2

48.0

62.0

61.9

0.1

57.3

68.2

59.7

0.4

53.7

67.7

57.4

0.3

49.3

66.7

67.5

0.0

63.7

73.2

58.0
63.5
61.6
57.8
59.1
63.0
68.2

0.6
0.6
3.8
0.2
1.8
1.6
0.0

51.9
57.9
56.4
52.6
53.2
57.4
64.5

66.1
71.4
71.5
63.7
67.9
71.6
73.0

55.2
60.7
55.0
57.4
56.0
60.0
65.3

0.7
0.5
7.1
2.1
2.0
1.6
0.0

48.3
53.9
47.4
51.3
49.3
53.3
61.0

63.8
68.7
68.0
65.2
65.3
68.9
70.6

63.8
69.5
69.4
67.7
67.2
69.7
71.6

0.1
0.1
0.2
0.1
0.4
0.2
0.0

58.8
64.8
64.9
63.8
62.9
65.0
68.1

70.6
75.3
75.3
73.3
73.6
75.4
75.9

62.0
68.0
66.1
63.1
65.0
67.9
70.7

0.5
0.2
1.7
0.1
0.8
0.5
0.0

56.2
62.0
60.5
57.8
59.7
62.2
66.9

70.5
75.4
75.5
69.8
73.2
75.6
75.8

61.7
67.6
67.2
68.2
66.0
68.3
71.2

0.3
0.1
0.4
0.0
0.4
0.2
0.0

56.7
62.6
62.6
64.9
61.8
64.2
68.1

69.3
74.8
74.4
72.1
73.1
74.6
75.2

67.2
73.5
73.1
70.9
72.5
74.1
73.6

0.2
0.0
0.1
0.0
0.1
0.1
0.0

63.4
70.1
69.2
67.1
69.2
70.8
70.6

74.2
79.1
79.1
75.2
78.3
79.3
77.9

62.1

1.7

56.9

71.0

58.8

1.9

52.9

68.3

67.9

0.5

63.0

74.8

66.3

0.9

60.9

74.9

66.0

0.5

61.5

73.8

72.1

0.2

68.0

78.5

50.5

7.5

46.1

60.5

47.5

8.6

42.7

58.2

57.7

1.6

54.0

63.6

56.2

2.8

51.6

64.5

56.5

1.5

52.2

63.7

61.9

0.6

58.4

67.6

64.3

0.3

58.3

71.8

62.0

0.1

55.1

69.1

69.7

0.0

64.4

75.6

69.1

0.0

63.2

75.8

67.5

0.0

62.2

74.7

73.4

0.0

69.5

79.4

medRxiv preprint doi: https://doi.org/10.1101/19003814; this version posted August 15, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

A4 iHALE for 200 diseases in 6 countries

67.1

0.2

62.3

73.2

63.0

0.9

57.6

70.5

71.5

0.0

67.6

76.3

70.5

0.3

65.5

77.2

70.1

0.0

65.8

75.3

75.3

0.0

71.7

80.1

68.0

0.0

63.4

73.3

65.5

0.0

60.7

71.1

72.1

0.0

68.3

76.7

71.0

0.0

66.6

76.7

70.7

0.0

67.0

75.4

75.0

0.0

71.7

79.7

55.8
64.2
35.4

0.6
0.1
38.2

50.8
59.1
9.8

62.4
70.6
58.2

53.5
63.1
39.2

0.7
0.0
26.7

48.1
57.9
15.4

60.6
69.3
57.4

64.1
70.3
62.5

0.1
0.0
2.3

59.6
66.4
56.1

69.8
75.3
72.4

60.0
69.5
49.9

0.4
0.0
13.0

55.2
64.7
37.5

66.8
75.7
65.5

61.1
70.4
60.8

0.2
0.0
1.5

56.6
66.5
54.0

67.2
75.2
70.3

67.0
75.5
71.9

0.1
0.0
0.7

62.8
72.2
68.3

72.6
80.0
79.1

60.1
58.3
62.4

0.1
0.5
0.4

50.9
52.3
57.0

69.7
66.4
70.3

59.3
55.3
59.3

0.0
0.5
0.6

51.6
48.5
53.1

68.0
63.9
67.7

69.1
63.8
67.9

0.0
0.1
0.1

64.1
59.0
63.3

75.3
70.6
74.3

68.2
62.2
66.6

0.0
0.3
0.2

62.3
56.5
61.3

75.5
70.6
74.6

69.8
62.0
65.8

0.0
0.2
0.2

65.6
57.1
61.0

75.6
69.5
73.1

74.2
67.9
71.8

0.0
0.1
0.1

70.7
64.1
68.1

80.0
74.3
78.0

62.8

1.6

56.7

71.8

59.4

1.9

52.7

69.1

68.6

0.5

63.7

75.6

67.0

0.9

61.6

75.8

66.8

0.5

61.4

74.7

72.9

0.2

68.7

79.4

64.1

0.3

58.3

71.8

61.2

0.4

54.3

69.1

69.7

0.0

64.4

75.6

68.4

0.2

62.4

75.8

68.1

0.1

63.6

75.2

73.8

0.0

70.2

79.4

68.1
64.0
59.9
47.2

0.0
0.9
0.1
3.0

64.0
58.3
51.5
38.9

73.4
71.7
69.3
56.8

67.8
60.9
57.3
36.1

0.0
1.3
0.1
4.4

63.8
54.3
48.4
30.4

72.9
69.0
66.5
41.4

73.8
70.1
65.5
49.4

0.0
0.2
0.0
0.9

70.7
65.2
58.7
40.9

77.9
76.2
73.8
59.0

73.8
68.7
64.4
36.9

0.0
0.4
0.0
3.3

70.6
63.1
55.8
30.2

78.3
76.4
74.1
42.1

73.4
69.6
65.5
62.7

0.0
0.1
0.0
0.1

70.6
65.1
59.6
58.3

77.6
75.3
73.0
69.0

77.7
74.5
71.6
69.1

0.0
0.1
0.0
0.0

75.2
70.9
67.6
65.9

81.2
80.0
78.6
74.0

67.3

0.1

62.9

72.9

65.3

0.0

60.7

70.9

72.0

0.0

68.2

76.6

69.8

0.0

65.2

75.5

70.9

0.0

67.5

75.2

75.6

0.0

72.5

79.6

64.4

1.6

59.9

72.4

62.2

1.1

56.7

70.3

71.6

0.1

67.7

76.9

67.0

0.3

60.8

74.9

71.4

0.0

68.2

75.9

76.5

0.0

73.8

80.7

57.2

0.9

51.5

64.8

54.1

1.0

47.9

61.8

62.9

0.2

58.0

69.6

58.0

0.4

52.0

65.4

62.1

0.1

56.7

69.1

69.9

0.0

66.4

75.3

66.1

0.7

61.5

73.0

64.2

0.9

59.7

71.1

72.3

0.1

68.3

77.0

70.8

0.2

66.3

77.0

71.6

0.0

67.9

75.9

76.6

0.0

73.2

80.7

63.3

0.3

58.3

69.8

61.7

0.4

56.6

68.5

68.4

0.2

63.3

75.1

68.5

0.2

63.5

75.2

69.8

0.0

65.7

75.1

74.9

0.0

71.7

80.1

47.8

4.7

32.7

62.1

49.9

1.6

38.4

61.0

64.0

0.4

57.9

72.9

58.7

0.9

48.8

70.4

63.5

0.2

57.3

72.2

70.8

0.1

66.7

77.9

61.2

0.4

55.9

68.0

62.4

0.2

57.2

69.0

69.2

0.0

65.1

74.3

69.7

0.1

65.3

75.7

68.0

0.0

64.1

73.0

74.9

0.0

71.5

79.7

57.3

0.0

50.8

64.3

56.1

0.0

49.3

62.8

67.4

0.0

62.4

74.3

63.3

0.0

56.5

71.1

61.5

0.0

54.3

69.2

70.8

0.0

66.4

77.2

64.6

0.0

58.3

71.8

60.5

0.0

53.5

68.3

69.3

0.0

64.4

75.5

68.1

0.0

62.4

75.7

68.7

0.0

64.3

74.6

73.7

0.0

70.2

79.4

62.1

0.1

55.0

70.2

59.4

0.0

51.9

67.5

68.9

0.0

63.6

75.4

63.3

0.0

55.7

71.9

66.4

0.0

60.5

73.6

71.9

0.0

67.4

78.6

53.7

3.9

47.1

64.0

52.9

4.5

46.5

63.1

65.8

0.9

60.9

73.7

61.2

1.4

54.7

71.0

60.8

0.4

53.2

70.1

69.9

0.3

65.3

76.9

52.0
59.6

0.6
0.3

42.8
53.0

61.7
68.8

53.7
59.0

0.7
0.2

47.5
52.6

62.0
66.8

60.9
68.9

0.1
0.0

56.2
64.3

68.3
74.7

60.4
67.7

0.5
0.1

55.1
62.2

68.1
75.1

57.5
69.2

0.5
0.0

50.3
64.9

66.5
75.2

65.8
74.6

0.1
0.0

62.4
70.8

71.6
79.9

61.6
65.2

1.2
0.1

56.0
59.8

70.3
71.8

58.3
62.3

1.4
0.1

51.9
55.9

67.6
69.7

67.1
70.2

0.4
0.0

62.4
65.2

74.0
75.6

65.6
69.6

0.9
0.0

60.0
64.0

74.3
76.4

65.3
68.7

0.5
0.0

60.7
63.6

73.2
74.6

71.4
74.1

0.2
0.1

67.8
70.2

78.0
79.4

medRxiv preprint doi: https://doi.org/10.1101/19003814; this version posted August 15, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

Benign and in situ
intestinal neoplasms
Benign prostatic
hyperplasia
Bipolar disorder
Bladder cancer
Brain and nervous
system cancer
Breast cancer
Bulimia nervosa
Cannabis use
disorders
Caries of deciduous
teeth
Caries of permanent
teeth
Cataract
Cellulitis
Cervical cancer
Chronic kidney
disease due to
diabetes mellitus
type 1
Chronic kidney
disease due to
diabetes mellitus
type 2
Chronic kidney
disease due to
glomerulonephritis
Chronic kidney
disease due to
hypertension
Chronic kidney
disease due to other
and unspecified
causes
Chronic lymphoid
leukemia
Chronic myeloid
leukemia
Chronic obstructive
pulmonary disease
Cirrhosis and other
chronic liver
diseases due to
alcohol use
Cirrhosis and other
chronic liver
diseases due to
hepatitis B
Cirrhosis and other
chronic liver
diseases due to
hepatitis C
Cirrhosis and other
chronic liver
diseases due to other
causes
Cocaine use disorders
Colon and rectum
cancer
Conduct disorder
Conflict and

46.4

17.5

31.9

64.5

26.8

43.0

0.5

45.2

42.7

25.5

18.7

66.6

30.4

40.3

1.4

51.7

50.2

9.2

35.9

67.0

62.5

4.2

56.0

73.9

50.3

8.3

46.3

60.8

46.6

10.8

41.4

58.4

57.8

1.9

54.2

63.9

55.9

3.5

51.1

64.7

56.3

2.1

52.4

63.9

61.9

1.0

58.7

67.9

63.8
63.9
67.3
42.7

0.2
0.9
0.6
4.0

58.4
58.3
62.9
37.7

71.3
71.7
73.6
49.4

61.3
60.0
65.0
35.8

0.2
2.5
0.3
9.4

55.5
53.5
59.9
30.3

69.0
69.0
72.3
43.0

69.8
69.8
74.4
51.8

0.0
0.1
0.0
2.5

65.5
65.2
71.3
47.8

75.5
75.6
78.8
58.2

68.5
68.5
73.3
42.0

0.1
0.6
0.1
4.9

63.6
63.1
69.9
35.0

75.7
76.4
78.9
50.0

68.5
68.1
73.3
59.1

0.1
0.2
0.0
0.6

64.5
63.6
70.5
53.1

74.7
74.6
77.6
67.5

74.3
74.7
77.6
66.3

0.0
0.1
0.0
0.4

71.0
71.0
75.1
62.4

79.5
80.0
81.7
73.0

62.5

0.1

57.4

69.3

59.9

0.1

54.3

66.8

67.5

0.0

63.1

73.2

65.9

0.0

60.5

72.8

67.5

0.0

63.4

73.1

73.3

0.0

70.1

78.2

46.3

24.4

21.0

66.6

34.3

41.3

0.5

61.7

57.4

13.0

56.1

71.6

57.4

11.2

53.3

71.7

61.8

3.6

57.9

70.7

68.6

1.7

65.6

75.9

34.9
41.8
64.7
66.2

38.5
37.5
0.2
0.0

0.5
4.2
59.0
61.5

59.8
69.0
71.7
72.6

33.9
36.9
62.1
64.8

34.8
41.7
0.2
0.0

1.3
6.1
55.9
60.1

55.2
64.5
69.7
70.5

47.7
59.4
70.4
71.9

19.0
16.6
0.0
0.0

34.7
57.9
65.9
68.1

66.5
75.6
75.5
76.6

50.6
53.0
69.3
70.6

14.6
21.3
0.1
0.0

41.0
25.1
63.9
66.2

67.7
74.4
76.4
76.5

52.7
57.8
68.7
69.8

5.6
15.0
0.0
0.0

45.2
53.6
64.3
65.8

65.3
74.0
75.2
75.0

65.3
73.9
74.5
75.2

2.6
2.3
0.0
0.0

62.1
71.7
70.9
72.0

72.9
80.0
79.3
79.8

30.0
61.8
63.3

35.8
0.1
1.9

14.3
55.9
57.5

42.6
69.7
71.7

31.8
60.0
61.2

37.8
0.1
1.4

9.0
53.4
55.1

51.0
67.8
69.7

51.0
67.6
70.4

8.9
0.0
0.2

36.3
62.8
66.0

66.8
74.1
76.3

45.3
66.9
69.5

17.2
0.0
0.5

27.5
61.2
64.7

66.1
74.5
77.1

60.3
65.7
69.8

1.8
0.0
0.1

53.6
60.8
65.8

71.0
72.9
75.9

68.3
71.6
75.3

1.7
0.0
0.0

64.2
67.8
71.7

77.4
77.9
80.7

36.8
57.5
63.6

14.1
0.2
0.6

26.3
50.6
57.5

46.2
65.2
71.7

39.5
55.2
60.1

8.3
0.2
1.5

30.5
48.9
53.5

48.4
61.4
69.0

56.6
63.0
69.3

1.8
0.0
0.1

50.4
57.8
64.4

65.6
69.0
75.6

53.5
59.7
67.6

2.0
0.2
0.4

46.8
52.5
61.6

61.7
67.7
75.8

58.8
60.5
67.3

0.7
0.0
0.2

53.3
54.4
62.1

66.5
66.7
74.6

64.3
68.6
73.5

0.6
0.0
0.4

59.1
62.9
70.2

72.4
75.1
79.4

63.0

2.2

57.5

71.7

60.5

1.1

54.3

69.0

69.4

0.5

64.4

75.6

67.1

2.0

62.3

75.8

67.9

0.6

63.6

74.6

74.1

0.2

71.0

79.4

64.7
64.3
63.2

0.7
0.0
1.7

59.1
58.3
58.2

72.4
71.7
71.7

62.0
61.2
58.7

1.0
0.0
3.8

55.9
54.3
52.6

69.8
69.0
69.0

70.1
69.2
69.2

0.2
0.0
0.3

65.2
64.3
64.4

75.6
75.5
75.6

70.6
68.4
67.9

0.3
0.0
0.9

66.3
62.3
62.4

77.1
75.8
76.4

70.0
67.5
67.9

0.1
0.0
0.3

65.8
62.1
62.9

75.9
74.6
74.6

75.7
73.4
73.7

0.0
0.0
0.1

72.4
69.4
70.2

80.7
79.4
79.4

63.9
63.1

0.7
1.6

58.3
57.5

71.7
71.7

62.3
59.9

0.8
3.3

56.7
54.3

69.7
69.7

70.0
69.7

0.0
0.4

65.2
65.2

75.6
75.6

70.1
68.7

0.1
0.8

65.5
63.9

76.4
76.4

68.3
69.8

0.1
0.2

63.6
65.8

74.6
75.9

74.1
75.5

0.0
0.1

70.2
72.4

79.4
80.7

64.1
59.3
59.4
65.9

1.0
7.0
7.0
0.2

58.3
54.3
54.3
60.7

71.8
71.1
71.1
72.5

62.0
55.8
55.9
63.0

0.8
7.9
7.8
0.1

55.9
49.4
50.2
56.8

69.8
68.3
68.3
69.8

71.5
67.9
68.0
71.5

0.0
1.5
1.5
0.0

67.6
63.7
63.7
67.6

77.0
74.9
74.9
76.3

70.2
65.9
66.1
70.2

0.2
2.4
2.2
0.0

65.5
60.0
60.8
64.8

77.2
75.8
75.8
76.5

70.9
66.2
66.3
70.8

0.1
1.2
1.1
0.0

67.2
61.4
61.4
67.2

75.9
74.6
74.7
75.9

76.4
72.6
72.8
76.1

0.0
0.5
0.5
0.0

73.2
68.7
68.7
73.2

80.7
79.4
79.4
80.7

56.5

0.4

49.2

64.4

56.1

0.2

49.3

62.9

62.4

0.0

56.9

69.7

60.2

0.1

52.4

67.7

66.8

0.0

61.4

73.3

71.4

0.0

66.9

77.3

64.5

0.4

58.9

71.6

62.4

0.3

56.6

69.6

70.8

0.0

66.6

76.1

70.0

0.1

65.3

76.9

69.9

0.0

65.8

75.2

74.5

0.0

70.8

79.9

65.2

0.0

59.1

72.4

62.5

0.1

56.7

69.8

70.5

0.0

66.0

75.6

69.6

0.0

63.9

76.4

69.4

0.0

65.1

75.3

75.1

0.0

71.7

80.0

65.7
68.4
67.5
39.9
55.8

0.0
0.0
0.0
23.2
3.2

60.6
64.7
62.2
20.9
49.0

72.4
72.6
73.1
60.4
66.5

62.6
67.3
64.7
46.2
57.0

0.0
0.0
0.0
8.2
1.5

56.8
63.5
59.1
31.9
49.9

69.7
71.7
71.2
60.5
66.3

70.9
72.4
71.6
68.5
68.0

0.0
0.0
0.0
0.4
0.3

66.7
69.0
67.5
63.4
64.0

76.2
76.4
76.3
74.6
73.5

70.4
72.7
71.1
61.2
68.0

0.0
0.0
0.0
2.3
0.9

65.5
69.3
66.3
53.0
63.5

77.0
76.9
77.1
72.7
74.9

70.4
72.1
70.6
67.1
65.8

0.0
0.0
0.0
0.1
0.3

66.4
69.0
66.5
62.6
61.0

75.3
76.1
75.3
74.4
73.0

75.3
76.5
75.7
72.9
74.4

0.0
0.0
0.0
0.1
0.1

71.7
73.8
72.4
69.2
71.4

80.0
80.1
80.0
79.1
78.9

61.6

1.1

56.3

69.7

58.8

1.0

52.8

67.1

67.9

0.1

63.4

74.0

66.4

0.4

61.2

74.1

66.3

0.2

62.0

72.9

72.1

0.0

68.7

77.9

46.0

3.5

39.2

54.7

35.2

12.3

25.0

44.5

65.1

0.2

61.3

70.4

58.8

1.6

52.2

68.5

62.4

0.1

58.1

68.5

66.4

0.1

62.9

71.8

61.5

0.8

56.8

68.9

60.2

0.7

55.1

67.4

68.5

0.1

64.5

73.9

67.7

0.2

63.3

73.8

69.0

0.0

65.3

74.2

73.1

0.0

70.1

77.7

64.1

1.8

60.2

71.3

58.1

3.3

52.0

67.7

69.5

0.2

65.8

74.7

65.6

0.9

59.8

73.8

66.3

0.2

62.1

72.1

72.1

0.1

68.5

76.8

medRxiv preprint doi: https://doi.org/10.1101/19003814; this version posted August 15, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

terrorism
Congenital heart
anomalies
Congenital
musculoskeletal and
limb anomalies
Contact dermatitis
Cyclist road injuries
Decubitus ulcer
Diabetes mellitus
type 1
Diabetes mellitus
type 2
Digestive congenital
anomalies
Down syndrome
Drowning
Dysthymia
Edentulism and severe
tooth loss
Endocarditis
Endometriosis
Environmental heat
and cold exposure
Epilepsy
Esophageal cancer
Executions and police
conflict
Exposure to forces of
nature
Falls
Female infertility
Fire, heat, and hot
substances
Foreign body in eyes
Foreign body in other
body part
Fungal skin diseases
G6PD deficiency
G6PD trait
Gallbladder and
biliary diseases
Gallbladder and
biliary tract cancer
Gastritis and
duodenitis
Gastroesophageal
reflux disease
Genital prolapse
Glaucoma
Gout
Hodgkin lymphoma
Hypertensive heart
disease
Idiopathic
developmental
intellectual
disability
Inflammatory bowel
disease
Inguinal, femoral,
and abdominal hernia
Interstitial lung

55.4

1.7

48.1

64.4

54.1

0.6

47.0

61.4

61.5

0.1

56.0

68.1

61.4

0.4

55.5

68.5

65.1

0.1

60.4

71.6

67.5

0.0

62.9

73.5

68.8

0.1

64.5

73.8

66.8

0.0

62.3

71.9

73.0

0.0

69.0

77.7

72.9

0.0

68.6

77.8

71.8

0.0

67.9

76.5

76.8

0.0

73.9

80.7

62.7
61.6
59.1
58.6
59.6

0.6
4.3
7.0
0.1
1.3

57.9
57.3
53.9
51.4
53.4

69.4
70.8
70.7
66.6
69.2

61.9
60.2
55.5
58.6
59.0

0.5
2.3
7.8
0.1
0.2

57.3
54.9
49.9
52.6
52.3

68.4
68.8
68.0
65.3
66.8

68.3
67.8
67.6
68.0
67.0

0.0
0.5
1.5
0.0
0.0

64.3
62.8
63.3
62.7
61.2

73.1
74.6
74.5
74.1
74.1

69.2
67.2
65.8
66.6
66.0

0.1
0.6
2.2
0.0
0.1

65.3
61.4
60.4
60.6
59.0

74.6
74.8
75.4
73.7
74.3

69.9
68.9
66.0
68.6
69.2

0.0
0.1
1.1
0.0
0.0

66.5
64.3
61.1
64.0
64.8

74.6
75.0
74.3
74.4
75.0

73.3
71.9
72.4
74.8
73.9

0.0
0.1
0.5
0.0
0.0

70.0
67.7
68.3
71.3
70.6

77.7
77.8
79.0
79.7
79.7

55.0

0.1

47.5

62.9

55.8

0.0

49.3

63.0

59.1

0.0

52.0

65.8

60.1

0.0

54.0

67.0

60.0

0.0

54.1

66.0

68.1

0.0

63.1

73.9

46.0

7.1

35.4

57.5

50.2

2.0

42.6

58.3

55.6

0.2

47.7

63.5

54.1

1.9

46.5

63.1

57.3

1.0

51.7

64.2

65.8

0.3

60.3

73.0

57.5

0.3

50.9

64.5

57.8

0.1

51.8

64.5

61.2

0.0

55.2

67.5

62.2

0.0

55.6

69.2

60.9

0.0

54.4

67.2

69.4

0.0

64.5

75.2

55.3

1.8

49.1

64.5

57.1

0.4

51.0

64.5

60.9

0.0

54.9

68.2

62.0

0.4

55.6

69.2

61.7

0.2

55.6

67.9

70.1

0.0

65.5

75.5

44.9

13.7

32.6

58.3

51.3

3.1

44.3

59.9

57.0

0.3

49.1

65.1

56.4

2.4

49.1

66.2

58.0

1.2

52.0

65.0

68.1

0.3

62.9

74.8

62.9
65.0

0.1
0.2

57.8
59.7

69.6
72.3

59.7
62.0

0.2
0.2

54.2
55.8

66.9
69.6

68.3
70.7

0.0
0.0

64.1
66.6

73.8
76.1

66.7
69.3

0.1
0.1

62.0
63.8

73.4
76.3

67.6
68.3

0.0
0.1

63.7
63.5

73.2
74.5

72.6
74.5

0.0
0.0

69.3
70.8

77.7
79.9

64.2
55.5

0.0
1.1

58.3
44.7

71.7
67.2

61.1
55.9

0.0
0.8

54.3
47.4

69.0
66.0

69.2
67.7

0.0
0.1

64.3
62.6

75.5
74.9

68.3
66.6

0.0
0.1

62.4
60.5

75.8
75.1

67.5
69.8

0.0
0.0

62.8
65.7

74.6
75.1

73.3
74.8

0.0
0.0

69.4
71.5

79.3
80.4

54.0
62.7
54.7
61.5

1.6
0.4
2.5
4.8

45.8
57.2
46.1
56.7

64.2
70.5
65.6
71.7

50.3
59.6
37.5
51.0

1.5
0.6
23.6
14.9

41.8
53.4
22.2
34.9

59.9
68.0
55.1
67.5

56.9
68.4
59.1
69.2

0.3
0.1
3.4
0.4

48.5
63.8
53.3
64.4

66.5
74.5
69.0
75.6

57.8
66.8
48.6
67.8

0.5
0.3
7.5
1.1

50.4
61.6
39.6
62.3

66.3
74.6
60.5
75.7

63.6
66.6
58.3
68.0

0.0
0.1
2.1
0.5

58.6
62.1
53.6
63.6

69.4
73.6
65.6
75.2

66.7
72.4
63.6
74.2

0.0
0.0
0.5
0.2

61.3
69.0
59.0
70.9

73.1
78.2
70.1
80.0

63.0

2.0

57.5

71.7

59.1

3.0

53.4

69.0

69.5

0.2

64.4

75.6

67.5

1.1

62.3

75.7

68.0

0.1

62.9

74.6

74.1

0.1

70.9

79.4

56.5
48.3
48.6

0.5
0.5
19.6

50.0
42.1
36.3

64.4
55.3
66.8

54.6
45.0
46.3

0.4
0.6
16.0

48.5
38.1
36.6

61.4
51.7
62.1

63.6
53.2
67.7

0.3
0.3
2.1

58.5
44.4
63.6

70.5
62.5
75.4

60.3
49.1
57.7

0.2
0.5
7.5

54.0
40.7
50.6

67.0
57.5
70.8

66.6
52.5
70.4

0.0
0.1
0.3

62.0
46.7
66.4

72.1
59.3
75.7

71.2
58.0
73.4

0.0
0.1
0.5

67.1
51.9
70.1

76.6
65.1
79.2

57.3
55.9
66.0
63.2
14.5
47.7
66.2

1.6
3.4
0.1
0.1
69.3
15.0
0.0

48.1
46.7
61.2
58.2
0.0
32.7
60.7

68.4
67.0
72.9
69.7
38.2
64.4
72.5

47.9
54.8
63.9
61.0
0.6
49.1
65.2

3.4
2.4
0.0
0.0
99.5
9.6
0.0

36.7
46.9
58.3
55.6
0.0
38.2
59.9

60.2
64.6
70.4
67.7
0.4
62.6
71.2

63.5
62.7
71.6
68.4
36.9
65.3
72.5

1.0
0.2
0.0
0.0
24.2
0.9
0.0

59.3
54.5
67.5
64.3
22.0
60.1
68.3

71.3
71.6
76.8
73.8
52.0
73.2
77.0

64.8
61.6
70.7
67.7
26.2
60.9
71.9

0.9
1.9
0.0
0.0
46.1
2.8
0.0

59.2
53.1
66.2
63.1
0.4
54.1
67.1

74.1
72.5
77.0
74.0
49.8
71.4
77.2

62.8
63.2
70.9
67.7
15.7
69.2
71.8

0.8
0.3
0.0
0.0
66.8
0.1
0.0

56.7
55.2
67.1
63.7
0.0
65.0
67.9

72.6
71.7
75.9
73.2
38.4
75.0
75.9

71.8
67.4
75.9
73.1
44.2
73.5
76.8

0.3
0.2
0.0
0.0
14.4
0.1
0.0

68.7
61.2
72.9
69.9
43.4
70.1
73.9

77.9
75.3
80.6
78.0
55.6
78.7
80.7

54.5

3.6

45.0

66.0

55.8

1.8

47.7

65.9

62.4

0.3

56.3

71.1

73.2

0.1

70.0

78.5

72.4

0.0

69.1

76.5

74.7

0.0

71.7

80.6

68.4

0.0

64.4

73.8

65.0

0.1

60.6

71.1

72.2

0.0

68.3

76.9

71.5

0.0

67.0

77.4

72.6

0.0

69.8

76.5

76.9

0.0

74.5

80.7

67.8

0.0

63.6

73.5

64.5

0.0

59.8

71.0

72.4

0.0

68.3

77.0

72.1

0.0

68.4

77.5

71.8

0.0

68.5

76.3

76.2

0.0

73.2

80.5

64.1

1.0

58.3

71.8

60.9

1.3

54.3

69.1

69.9

0.2

65.2

75.6

69.2

0.4

64.0

76.5

68.6

0.1

64.4

75.3

74.4

0.0

71.0

79.4

48.5

0.3

43.7

53.7

46.9

0.4

41.4

52.6

53.4

0.1

47.8

58.6

51.5

0.3

45.5

57.7

43.5

1.5

33.9

52.0

58.6

0.1

52.5

65.1

medRxiv preprint doi: https://doi.org/10.1101/19003814; this version posted August 15, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

disease and pulmonary
sarcoidosis
Intracerebral
hemorrhage
Ischemic heart
disease
Ischemic stroke
Kidney cancer
Klinefelter syndrome
Larynx cancer
Lip and oral cavity
cancer
Liver cancer due to
alcohol use
Liver cancer due to
hepatitis B
Liver cancer due to
hepatitis C
Liver cancer due to
NASH
Liver cancer due to
other causes
Low back pain
Major depressive
disorder
Male infertility
Malignant skin
melanoma
Mesothelioma
Migraine
Motor neuron disease
Motor vehicle road
injuries
Motorcyclist road
injuries
Multiple myeloma
Multiple sclerosis
Myelodysplastic,
myeloproliferative,
and other
hematopoietic
neoplasms
Myocarditis
Nasopharynx cancer
Near vision loss
Neck pain
Neural tube defects
Non-Hodgkin lymphoma
Non-melanoma skin
cancer (basal-cell
carcinoma)
Non-melanoma skin
cancer (squamous-cell
carcinoma)
Non-rheumatic
calcific aortic valve
disease
Non-rheumatic
degenerative mitral
valve disease
Non-venomous animal
contact
Opioid use disorders

55.8
66.4
65.1

10.3
0.0
0.9

51.9
61.6
59.9

69.1
72.4
72.5

53.5
64.1
62.6

10.3
0.0
1.0

47.7
58.9
56.8

67.2
70.1
70.5

65.9
70.0
70.6

1.9
0.0
0.1

62.0
65.6
66.0

73.0
75.4
76.3

64.2
70.2
69.9

2.8
0.0
0.4

59.2
65.7
64.8

73.9
76.3
76.5

64.9
69.7
70.1

1.3
0.0
0.0

60.1
65.6
65.8

73.1
75.0
75.3

71.2
74.5
74.8

0.5
0.0
0.1

67.2
71.1
71.0

77.7
79.5
80.1

49.8
63.0

6.4
0.5

34.7
57.2

65.9
71.3

40.4
61.8

13.0
0.3

26.0
56.4

55.6
69.5

60.8
70.6

2.3
0.0

56.2
67.0

69.8
75.3

57.5
70.3

3.8
0.0

48.0
66.3

70.6
76.1

59.7
70.5

2.7
0.0

52.9
67.4

71.0
75.2

70.7
75.5

0.8
0.0

67.4
72.8

77.5
79.7

52.6

9.8

48.5

64.9

36.0

34.6

0.5

58.9

59.9

4.6

55.8

68.5

52.9

13.1

46.2

68.2

14.8

75.6

0.0

13.2

62.8

6.8

60.6

73.0

41.0

23.3

26.7

57.8

5.0

90.9

0.0

0.4

55.6

9.7

53.6

66.8

31.1

46.7

0.4

60.8

43.0

23.0

25.2

60.9

50.5

14.5

49.1

63.9

63.4

1.5

57.5

71.7

60.9

1.0

54.3

69.1

69.6

0.2

64.4

75.6

68.6

0.3

63.2

76.4

68.3

0.1

63.6

74.6

74.2

0.0

71.0

79.4

63.7

0.1

57.9

71.5

60.8

0.1

54.1

68.8

69.1

0.0

64.2

75.3

68.2

0.0

62.8

75.7

67.3

0.0

62.5

74.4

73.0

0.0

69.3

79.2

80.9

0.0

80.2

81.5

80.6

0.0

79.8

81.1

83.2

0.0

82.3

84.0

82.6

0.0

81.6

83.3

79.6

0.0

78.9

80.2

82.8

0.0

81.9

83.1

41.3
45.2

33.8
20.1

11.7
25.3

65.6
63.7

49.2
47.8

14.8
13.5

37.4
36.3

65.0
62.8

62.5
70.1

5.0
0.2

57.6
65.7

73.9
76.0

55.6
55.3

10.8
8.3

42.8
44.7

72.0
70.3

66.5
65.9

1.1
0.5

62.5
60.5

73.9
73.6

71.3
75.4

0.5
0.1

67.1
72.2

77.9
80.4

63.6
53.0
59.8
64.2
65.0

1.0
1.1
0.6
0.6
0.7

57.5
45.8
54.2
58.3
59.1

71.8
61.2
67.0
71.7
72.5

60.8
54.7
59.9
61.2
62.8

0.9
0.4
0.9
1.4
0.6

54.3
48.4
54.2
55.1
56.8

69.1
61.5
69.1
69.7
69.8

69.6
62.6
66.9
69.8
71.1

0.1
0.1
0.1
0.1
0.0

64.4
56.1
62.7
65.2
66.8

75.6
70.5
73.2
75.6
76.3

68.2
59.8
68.6
69.0
70.1

0.4
0.3
0.2
0.4
0.2

62.4
53.1
64.7
63.9
65.5

75.8
67.0
74.6
76.4
76.5

67.9
66.7
66.6
68.6
70.2

0.2
0.0
0.1
0.3
0.0

62.9
61.2
62.5
64.4
65.8

74.6
73.1
72.4
75.3
75.3

73.7
68.3
71.9
74.8
75.7

0.0
0.0
0.0
0.0
0.0

70.2
62.7
68.5
71.7
72.5

79.4
74.8
76.3
80.0
80.1

63.7

1.3

58.3

71.7

55.9

8.9

51.0

69.0

70.2

0.2

65.2

76.3

68.5

1.3

63.9

76.4

69.4

0.2

65.1

75.3

75.6

0.0

72.4

80.7

63.7

1.3

58.3

71.7

60.9

1.8

55.1

69.7

70.1

0.2

65.2

75.6

69.1

0.4

63.9

76.4

69.3

0.1

65.1

75.3

74.7

0.0

71.0

80.0

63.2
58.1
57.5
64.9
36.1

0.4
0.5
0.4
0.4
31.7

58.4
50.4
50.9
59.1
14.5

69.8
67.5
65.2
72.4
56.6

61.9
56.7
55.8
63.2
34.1

0.2
0.3
0.2
0.2
37.4

56.7
49.0
49.3
57.5
4.1

68.7
65.3
62.9
70.5
57.4

70.8
63.6
60.8
71.0
63.0

0.0
0.0
0.0
0.0
4.7

67.0
56.7
54.5
66.7
59.3

75.8
71.5
67.4
76.3
73.2

68.9
62.8
59.7
69.9
49.2

0.1
0.2
0.1
0.1
16.7

64.6
54.5
52.4
64.7
35.0

75.1
72.5
67.0
77.1
68.5

70.0
64.8
62.1
70.0
68.0

0.0
0.0
0.0
0.0
0.7

66.4
58.6
55.8
65.8
64.2

75.3
71.9
68.6
75.3
74.4

75.7
69.9
67.9
75.0
69.4

0.0
0.0
0.0
0.0
0.4

72.9
63.8
62.1
71.7
63.8

80.1
77.9
74.5
80.0
76.4

67.0
63.4

0.0
2.2

63.3
58.3

71.7
71.7

64.9
55.3

0.0
11.2

61.1
49.3

69.7
69.0

69.5
69.5

0.0
0.7

65.9
65.2

74.0
75.6

69.9
67.3

0.0
2.5

66.5
63.1

74.4
76.4

69.0
68.2

0.0
0.5

65.8
64.3

73.0
75.2

73.1
74.8

0.0
0.2

70.0
71.7

77.1
80.0

64.9
65.8
68.6

0.3
0.0
0.0

59.0
59.9
63.8

72.3
72.5
73.7

63.1
62.8
66.6

0.3
0.0
0.0

57.4
56.8
61.5

70.5
69.8
71.8

70.9
70.9
72.1

0.0
0.0
0.0

66.7
66.0
68.2

76.2
76.3
76.9

71.8
69.6
72.2

0.1
0.0
0.0

67.7
64.0
67.8

78.3
76.5
77.1

70.8
70.0
71.4

0.0
0.0
0.0

67.2
65.8
67.9

75.8
75.3
75.9

75.6
75.3
76.3

0.0
0.0
0.0

72.3
71.7
73.1

80.6
80.0
80.6

58.5

7.0

53.4

71.1

40.6

20.9

20.8

62.2

69.6

0.4

65.2

76.2

50.8

12.6

24.2

73.0

64.2

3.4

59.9

74.6

74.0

0.1

70.2

79.4

63.4

1.5

57.5

71.7

57.3

6.4

51.8

69.0

69.6

0.2

64.4

75.6

63.7

4.5

57.5

75.8

67.5

0.4

62.9

75.2

73.6

0.2

70.2

79.4

63.7

1.0

58.3

71.8

58.6

2.9

52.7

69.0

69.3

0.2

64.4

75.6

67.3

1.1

61.6

75.8

67.4

0.2

62.2

74.6

73.6

0.1

70.2

79.4

61.3

4.4

56.6

71.7

48.6

20.1

35.7

67.5

66.0

3.4

62.8

75.5

62.1

9.2

58.3

75.7

66.9

1.3

62.8

74.6

73.8

0.2

70.2

79.9

59.5

6.9

55.0

71.6

53.0

13.0

46.8

67.5

68.0

1.7

64.3

75.5

65.1

4.0

59.9

75.7

68.2

0.7

64.3

75.2

74.1

0.1

70.9

79.9

63.4

0.4

58.0

71.5

60.1

0.7

53.2

68.8

69.1

0.1

64.2

75.5

67.4

0.3

62.1

75.6

67.4

0.2

62.6

74.6

73.0

0.1

69.2

79.1

64.0
66.2
64.5
61.1
53.2

0.2
0.0
0.7
0.5
16.9

58.3
62.1
59.1
56.0
46.7

71.8
70.8
72.5
68.4
70.3

61.0
65.7
62.1
59.1
25.2

0.2
0.0
0.6
0.5
60.9

54.3
61.5
55.9
53.5
0.5

69.1
70.5
69.8
66.5
59.1

69.3
71.9
70.7
67.8
67.4

0.0
0.0
0.1
0.0
3.1

64.4
68.2
66.0
63.6
63.6

75.6
76.0
76.3
73.4
75.6

68.2
72.1
69.5
66.1
36.5

0.1
0.0
0.2
0.2
43.6

62.4
68.3
64.0
61.3
3.4

75.8
76.9
76.5
73.1
67.8

67.6
71.2
69.6
65.9
67.2

0.1
0.0
0.1
0.1
4.6

62.2
67.0
65.1
61.8
65.1

74.6
75.6
75.3
72.1
75.8

73.3
76.1
75.3
71.9
74.7

0.0
0.0
0.0
0.0
1.6

69.5
72.9
71.7
68.4
72.4

79.4
80.3
80.0
77.1
80.7

medRxiv preprint doi: https://doi.org/10.1101/19003814; this version posted August 15, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

Orofacial clefts
Osteoarthritis
Other benign and in
situ neoplasms
Other cardiomyopathy
Other cardiovascular
and circulatory
diseases
Other chromosomal
abnormalities
Other congenital
birth defects
Other exposure to
mechanical forces
Other gynecological
diseases
Other
hemoglobinopathies
and hemolytic anemias
Other leukemia
Other malignant
neoplasms
Other oral disorders
Other pharynx cancer
Other pneumoconiosis
Other road injuries
Other skin and
subcutaneous diseases
Other transport
injuries
Other unintentional
injuries
Other vision loss
Ovarian cancer
Pancreatic cancer
Pancreatitis
Paralytic ileus and
intestinal
obstruction
Parkinson's disease
Pedestrian road
injuries
Peptic ulcer disease
Periodontal diseases
Peripheral artery
disease
Physical violence by
firearm
Physical violence by
other means
Physical violence by
sharp object
Poisoning by carbon
monoxide
Poisoning by other
means
Polycystic ovarian
syndrome
Premenstrual syndrome
Prostate cancer
Pruritus
Psoriasis
Pulmonary aspiration

63.1
62.2
58.0

1.5
0.7
1.8

57.5
57.1
53.6

71.8
69.8
66.0

61.5
61.0
47.8

1.6
0.5
4.4

55.9
55.3
40.7

69.8
68.7
57.4

70.8
69.5
61.0

0.2
0.1
0.6

66.8
65.6
57.3

76.3
75.1
67.1

69.3
68.3
60.9

0.5
0.2
1.0

64.0
63.6
55.2

76.5
75.2
69.3

68.6
67.5
66.0

0.2
0.1
0.3

64.4
63.5
60.6

75.3
74.0
73.3

74.7
74.3
73.3

0.1
0.0
0.1

71.0
71.3
70.1

80.0
79.4
78.7

61.3
63.5
41.1
63.5

0.3
0.9
0.5
0.8

56.3
57.5
35.6
58.1

67.9
71.8
46.0
71.5

58.9
60.6
40.7
60.9

0.3
1.0
0.5
0.7

53.6
54.3
35.3
54.9

65.8
69.1
45.5
69.0

66.9
69.8
45.7
69.6

0.0
0.1
0.1
0.1

62.8
65.2
39.3
65.1

72.1
75.6
51.4
75.5

65.4
68.1
44.4
68.3

0.1
0.4
0.2
0.3

60.6
62.4
38.7
63.3

71.9
75.8
49.7
75.8

66.3
68.0
43.5
68.3

0.0
0.2
0.2
0.1

62.4
63.6
38.2
64.2

71.6
74.6
47.9
74.8

70.8
74.2
48.6
74.4

0.0
0.1
0.0
0.0

67.2
71.0
42.1
71.2

75.9
79.4
54.4
79.8

61.2
59.5

5.1
6.7

54.2
54.2

73.1
71.0

53.4
50.5

9.4
12.2

38.4
31.5

68.3
66.8

71.1
66.7

0.9
2.7

67.5
62.8

77.0
75.6

56.4
47.2

11.9
21.3

35.1
21.4

74.4
71.5

45.9
66.2

11.8
1.4

30.0
61.4

61.4
74.6

74.8
70.2

1.1
1.7

72.4
67.1

80.7
79.4

64.2
3.6
59.3
57.7
53.8
57.4

0.2
100.0
7.0
0.2
0.5
2.1

58.3
0.5
54.2
51.8
45.0
52.7

71.8
4.8
70.9
64.2
63.5
65.2

61.3
24.3
55.7
55.1
55.0
51.1

0.3
31.4
7.8
0.9
0.3
2.4

54.3
15.2
50.1
47.9
47.7
44.1

69.1
34.0
68.2
63.6
63.5
59.9

69.9
13.1
67.8
65.4
64.7
60.5

0.0
80.5
1.5
0.0
0.0
0.4

65.2
8.3
63.5
60.0
59.5
55.9

75.6
17.7
74.8
72.5
71.2
66.7

68.8
2.6
66.0
64.2
62.0
62.0

0.1
99.6
2.2
0.1
0.1
1.0

63.2
0.5
60.7
59.0
54.2
57.7

75.8
3.1
75.6
70.8
71.4
69.0

68.0
19.4
66.3
65.2
66.0
63.9

0.1
43.6
1.1
0.1
0.0
0.2

63.6
3.2
61.4
60.9
60.6
60.2

74.6
29.0
74.6
70.9
73.2
69.5

74.0
26.3
72.7
70.9
72.0
68.2

0.0
43.5
0.5
0.0
0.0
0.0

70.2
9.5
68.6
67.1
67.6
65.4

79.4
39.3
79.3
75.2
78.1
72.6

64.2
54.4
16.9
58.9
62.1
57.8

0.4
2.5
57.9
7.1
1.0
0.2

58.3
36.9
3.0
53.8
56.5
51.7

71.8
69.3
30.0
70.5
70.8
65.2

61.4
51.6
18.9
55.4
61.4
55.5

0.4
3.8
49.2
7.8
0.2
0.2

55.1
34.8
3.0
49.8
55.1
49.3

69.1
65.8
32.3
67.7
68.8
62.2

70.1
69.1
31.3
67.6
69.6
62.0

0.0
0.1
23.4
1.5
0.0
0.0

65.2
64.9
20.7
63.3
65.0
56.9

75.6
75.3
41.7
74.5
75.4
68.3

68.8
65.3
9.5
65.7
69.1
60.9

0.2
0.6
89.9
2.2
0.0
0.2

63.2
59.1
4.2
60.4
63.7
54.1

75.8
74.8
11.5
75.2
75.5
67.8

68.7
67.0
25.8
66.1
69.6
62.9

0.1
0.0
35.3
1.1
0.0
0.0

64.4
61.9
16.1
61.2
65.6
57.4

75.3
74.4
35.9
74.4
75.1
68.5

74.5
72.8
27.6
72.5
74.7
69.7

0.0
0.0
21.9
0.5
0.0
0.0

71.0
68.4
20.4
68.5
70.9
64.7

79.4
79.1
33.1
79.2
79.8
75.6

58.4
63.2

7.1
1.7

53.3
57.5

69.9
71.7

54.9
59.7

7.8
2.4

49.3
53.5

67.2
69.0

66.8
69.6

1.5
0.2

62.5
64.4

73.6
75.6

65.0
68.4

2.2
0.5

59.7
63.2

74.5
76.5

65.2
67.6

1.2
0.3

60.4
62.9

73.4
74.6

71.5
74.3

0.5
0.1

67.5
71.0

78.1
80.0

63.3

1.2

57.5

71.7

60.6

1.1

54.3

69.1

70.2

0.1

65.2

75.6

68.1

0.4

62.4

75.8

69.9

0.1

65.8

75.3

74.1

0.1

71.0

79.4

46.9

13.1

48.4

57.2

40.4

17.5

37.6

52.3

60.0

2.2

55.1

68.7

52.3

9.0

42.6

67.6

61.4

3.8

56.7

70.9

67.6

3.1

64.6

75.6

65.4
63.1
63.1
64.4
55.5

0.1
1.5
0.1
0.0
6.2

59.9
57.5
57.4
58.8
47.3

72.4
71.7
70.7
71.5
67.9

62.8
60.3
61.0
61.4
56.8

0.1
1.5
0.1
0.0
1.8

56.7
53.5
55.0
54.9
48.4

69.7
69.0
68.2
68.8
66.7

70.9
69.6
69.2
69.1
65.6

0.0
0.2
0.0
0.0
0.1

66.7
64.4
64.2
64.2
60.1

76.2
75.6
75.3
75.2
72.5

70.0
68.0
69.0
68.4
63.4

0.1
0.5
0.0
0.0
1.1

64.7
62.3
62.9
62.2
55.7

76.4
75.7
75.8
75.5
72.2

69.9
68.1
70.1
67.6
68.5

0.0
0.2
0.0
0.0
0.1

65.8
63.6
65.6
62.7
64.3

75.2
74.6
75.6
74.4
74.5

75.2
74.1
73.5
73.1
73.6

0.0
0.1
0.0
0.0
0.0

71.7
70.2
69.9
69.2
70.1

80.0
79.4
79.2
79.1
78.6

63.6

1.6

58.3

71.7

60.7

1.3

55.0

69.0

69.7

0.3

65.2

75.6

68.5

1.2

63.9

76.4

68.4

0.1

64.3

74.6

74.3

0.0

70.9

79.4

63.1
NA

1.2
NA

57.5
NA

71.7
NA

59.9
NA

1.4
NA

53.5
NA

69.1
NA

69.2
69.7

0.3
0.0

64.4
66.3

75.6
74.6

67.4
66.2

0.6
0.1

61.6
62.5

75.8
72.1

67.6
65.5

0.3
0.0

62.9
61.0

74.6
71.0

73.5
72.3

0.1
0.0

69.4
69.1

79.4
76.5

medRxiv preprint doi: https://doi.org/10.1101/19003814; this version posted August 15, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

and foreign body in
airway
Pyoderma
Refraction disorders
Rheumatic heart
disease
Rheumatoid arthritis
Scabies
Schizophrenia
Seborrhoeic
dermatitis
Self-harm by firearm
Self-harm by other
specified means
Sexual violence
Sickle cell disorders
Sickle cell trait
Silicosis
Stomach cancer
Subarachnoid
hemorrhage
Tension-type headache
Testicular cancer
Thalassemias
Thalassemias trait
Thyroid cancer
Tracheal, bronchus,
and lung cancer
Turner syndrome
Unintentional firearm
injuries
Urinary tract
infections
Urogenital congenital
anomalies
Urolithiasis
Urticaria
Uterine cancer
Uterine fibroids
Vascular intestinal
disorders
Venomous animal
contact
Viral skin diseases
Coal workers
pneumoconiosis

medRxiv preprint doi: https://doi.org/10.1101/19003814; this version posted August 15, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-ND 4.0 International license .

1
2

References

GBD Causes of Death Collaborators,

2.

Das Gupta, P.,

4
5
6
7

Global, regional, and national age-sex-specific mortality
for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for
the Global Burden of Disease Study 2017.
392
Standardization and Decomposition of Rates: A User‚Äôs Manual. U.S.
Department of Commerce, Economics and Statistics Administration

1.

3

Lancet, 2018.

(10159): p. 1736-1788.

, B.o.t. Census, Editor.

1993.

37

